P Peromaa-Haavisto1, H Tuomilehto2, J Kössi3, J Virtanen4, M Luostarinen5, J Pihlajamäki6, P Käkelä7, M Victorzon8. 1. Hatanpää City Hospital, Department of Surgery, Tampere, Finland. Electronic address: pipsa.peromaa@kolumbus.fi. 2. Oivauni Sleep Clinic, Kuopio, Finland; Oivauni Sleep Clinic, Tampere, Finland; Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Finland. Electronic address: henri.tuomilehto@oivauni.fi. 3. Kantahäme Central Hospital, Department of Surgery, Hämeenlinna, Finland; University of Turku, Turku, Finland. Electronic address: jyrki.kossi@khshp.fi. 4. Lahti Region Central Hospital, Department of Surgery, Lahti, Finland. Electronic address: juha.virtanen@phsotey.fi. 5. Lahti Region Central Hospital, Department of Surgery, Lahti, Finland. Electronic address: markku.luostarinen@phsotey.fi. 6. Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Finland; Clinical Nutrition and Obesity Center, Kuopio University Hospital, Kuopio, Finland. Electronic address: jussi.pihlajamaki@uef.fi. 7. Clinical Nutrition and Obesity Center, Kuopio University Hospital, Kuopio, Finland. Electronic address: pirjo.kakela@kuh.fi. 8. Vaasa Central Hospital, Department of Surgery, Vaasa, Finland; University of Turku, Turku, Finland. Electronic address: mikael.victorzon@vshp.fi.
Abstract
BACKGROUND: Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder, particularly in bariatric patients. It is known to be tightly linked with metabolic abnormalities and cardiovascular morbidity. Obesity is the most noteworthy individual risk factor for OSA. The aim of this study was to investigate the effect of a laparoscopic Roux-en-Y gastric bypass (LRYGB) on OSA one year after surgery. METHODS: In this prospective multicenter study standard overnight cardiorespiratory recording was conducted 12 months after bariatric surgery in 132 patients who had OSA in the baseline recording prior to the operation. The main outcome measures were changes in the prevalence of OSA and apnea-hypopnea index (AHI). In addition, the changes in anthropometric and demographic measurements including weight, body mass index (BMI), and waist and neck circumference were evaluated. A sleep symptom questionnaire was administered at baseline and at 12 months. RESULTS: The prevalence of OSA decreased from 71% at baseline to 44% at 12 months after surgery (p < 0.001). OSA was cured in 45% and cured or improved in 78% of the patients, but moderate or severe OSA still persisted in 20% of the patients after the operation. De novo OSA occurred in eight percent of the patients, and total AHI decreased from 27.8 events/h to 9.9 events/h (p < 0.001). CONCLUSIONS: LRYGB is effective in treating OSA. However, the findings demonstrate that a postoperative cardiorespiratory recording is needed in order to identify the patients with persistent moderate to severe OSA after the operation. CLINICAL TRIAL REGISTRATION: ClinalTrials.gov; No.: NCT01080404; URL: www.clinicaltrials.gov.
BACKGROUND: Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder, particularly in bariatric patients. It is known to be tightly linked with metabolic abnormalities and cardiovascular morbidity. Obesity is the most noteworthy individual risk factor for OSA. The aim of this study was to investigate the effect of a laparoscopic Roux-en-Y gastric bypass (LRYGB) on OSA one year after surgery. METHODS: In this prospective multicenter study standard overnight cardiorespiratory recording was conducted 12 months after bariatric surgery in 132 patients who had OSA in the baseline recording prior to the operation. The main outcome measures were changes in the prevalence of OSA and apnea-hypopnea index (AHI). In addition, the changes in anthropometric and demographic measurements including weight, body mass index (BMI), and waist and neck circumference were evaluated. A sleep symptom questionnaire was administered at baseline and at 12 months. RESULTS: The prevalence of OSA decreased from 71% at baseline to 44% at 12 months after surgery (p < 0.001). OSA was cured in 45% and cured or improved in 78% of the patients, but moderate or severe OSA still persisted in 20% of the patients after the operation. De novo OSA occurred in eight percent of the patients, and total AHI decreased from 27.8 events/h to 9.9 events/h (p < 0.001). CONCLUSIONS: LRYGB is effective in treating OSA. However, the findings demonstrate that a postoperative cardiorespiratory recording is needed in order to identify the patients with persistent moderate to severe OSA after the operation. CLINICAL TRIAL REGISTRATION: ClinalTrials.gov; No.: NCT01080404; URL: www.clinicaltrials.gov.
Authors: Stephen A Glazer; Ann L Erickson; Ross D Crosby; Jennifer Kieda; Agata Zawisza; Mervyn Deitel Journal: Obes Surg Date: 2019-04 Impact factor: 4.129
Authors: Paweł Nastałek; Kamil Polok; Natalia Celejewska-Wójcik; Aleksander Kania; Krzysztof Sładek; Piotr Małczak; Piotr Major Journal: Sci Rep Date: 2021-03-02 Impact factor: 4.379
Authors: David Kent; Jeffrey Stanley; R Nisha Aurora; Corinna G Levine; Daniel J Gottlieb; Matthew D Spann; Carlos A Torre; Katherine Green; Christopher G Harrod Journal: J Clin Sleep Med Date: 2021-12-01 Impact factor: 4.062